Inspire Pharmaceuticals

Inspire discovers and develops new drugs to treat diseases characterized by deficiencies in the body's innate defense mechanisms of mucosal hydration and mucociliary clearance, as well as other non-mucosal disorders. These mechanisms are the natural way that the body defends its mucosal surfaces against dust, pollutants, bacteria and viruses. Mucosal hydration involves the moistening of the body's mucosal surfaces, and mucociliary clearance involves a blanket-like movement of fluid and particles from the lungs and sinuses. Mucosal surfaces are tissues containing specialized cells that lubricate and protect surfaces of organs that are directly exposed to the outside environment, such as the lungs, eyes and sinuses. Our lead products target respiratory and ophthalmic diseases with inadequate current treatments and which represent large market opportunities. We currently have six product candidates in clinical development, and we have entered into development and commercialization alliances with Allergan, Inc., Kissei Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., and Kirin Brewery Co., Ltd. Our products are based on our proprietary technology relating to P2Y receptors. We are exploring other target diseases where we believe P2Y receptors play important biological roles.

Contact Details: 4222 Emperor Boulevard Suite 470 Durham NC 27703 United States of America Tel: 919 941 9777 Fax: 919 941 9797 Email: info@inspirepharm.com WWW: www.inspirepharm.com/

Loading...

Recent Publications by Inspire Pharmaceuticals:
Adenosine analogues as inhibitors of P2Y12 receptor mediated platelet aggregation. Modified adenosine derivatives may lead to the development of P2Y(12)...	10th June, 2008	Inspire Pharmaceuticals, Inc., Department of Medicinal Chemistry, 4222	Bioorg Med Chem Lett. 2008 Mar 15;18(6):2167-71. Epub 2008 Jan 13. DOI Direct Link
Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. Platelet P2Y12 receptors play a central role in the regulation of platelet...	20th May, 2008	Departments of Chemistry, Inspire Pharmaceuticals, Inc., 4222 Emperor	J Med Chem. 2008 Feb 28;51(4):1007-25. Epub 2008 Jan 31. DOI Direct Link
Denufosol: A review of studies with inhaled P2Y(2) agonists that led to Phase 3. Among the most promising of the new therapies being developed for the...	16th February, 2008	Development, Inspire Pharmaceuticals, Inc., 4222 Emperor Blvd, Suite 200,	Pulm Pharmacol Ther. 2008;21(4):600-7. Epub 2007 Dec 31. DOI Direct Link
Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. P2Y(12) receptors participate in ADP-induced activation and aggregation of...	24th October, 2007	Inspire Pharmaceuticals Inc., 4222 Emperor Blvd Suite 200, Durham, NC	Platelets. 2007 Aug;18(5):346-56. DOI Direct Link
Randomization-based nonparametric methods for the analysis of multicentre trials. Multicentre trials offer several advantages over single centre trials in...	19th August, 2005	Inspire Pharmaceuticals Inc., Durham, North Carolina, USA.	Stat Methods Med Res. 2005 Jun;14(3):281-301.
→View more Inspire Pharmaceuticals research publications.

BioNews Results for Inspire Pharmaceuticals:
Haze and Irregular Astigmatism After PRK	CRS Today:  Aug 17 2008 6:54AM Matching: inspire pharmaceuticals
Dry Eye and Refractive Surgery	CRS Today:  Aug 17 2008 6:55AM Matching: inspire pharmaceuticals
InSite Vision Reports Second Quarter 2008 Financial Results	DiGiTAL50:  Aug 16 2008 12:53AM Matching: inspire pharmaceuticals
Noble Financial Capital Markets M.A.D. MAX Equity Conference Presenter Profiles	Pharma Live:  Aug 15 2008 7:09PM Matching: inspire pharmaceuticals
Noble Financial Capital Markets M.A.D. MAX Equity Conference Presenter Profiles	Genetic Engineering News:  Aug 15 2008 4:11PM Matching: inspire pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Inspire Pharmaceuticals news.

Inspire Pharmaceuticals Patents:
US Patent No.	Title
6143279	Uridine 5'-diphosphate and analogs useful for treating lung diseases
6555675	Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
6596725	Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
6624150	Method of treating gastrointestinal tract disease with purinergic receptor agonists
6673779	Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
→View more Inspire Pharmaceuticals patents.

Inspire Pharmaceuticals (ISPH) Financial information Links from Barchart
ISPH Quote from from Barchart.com
ISPH Chart from from Barchart.com
ISPH Profile from from Barchart.com
ISPH Opinion from from Barchart.com
→View more Inspire Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 184 times since April 2007, the link to the organisation's website has been followed 25 times

Recent Search Terms used to find this page: gsk medchem layoffs | INS115644 receptor | Inspire pharmaceuticals sputum | INS115644 | .

Search for more companies in Durham

Search for more companies in NC

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Inspire Pharmaceuticals